FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.
You may also be interested in...
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study
Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.
Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line
GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.
Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line
GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.